SCM
APTO

Silverarc Capital Management’s Aptose Biosciences, Inc. APTO Stock Holding History

Silverarc Capital Management’s Portfolio APTO Stock Details APTO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-222
Closed -$598K – 124
2021
Q1 		$598K Buy
+222
New +$440K 0.33% 66

Other funds holding APTO

DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
SMH
Sanders Morris Harris Houston, Texas $172M AUM 22.54% 1-Year Est. Return
PAWC
P.A.W. Capital Greenwich, Connecticut $88.2M AUM 25.13% 1-Year Est. Return

Silverarc Capital Management's APTO Position: Q2 2021 in Review

Silverarc Capital Management sold out of Aptose Biosciences, Inc. (APTO) in Q2 2021, closing a stake of 222 shares — an estimated $598K sold.

Silverarc Capital Management first reported a position in APTO in Q1 2021 and held it in 1 quarter. The position peaked at $598K in Q1 2021. 63 funds tracked by Wall St. Rank hold APTO as of Q2 2021.

  • Silverarc Capital Management reported no remaining Aptose Biosciences, Inc. position as of Q2 2021 after selling out during the quarter.
  • Silverarc Capital Management sold 222 Aptose Biosciences, Inc. shares in Q2 2021, an estimated $598K.
  • Silverarc Capital Management first reported a position in Aptose Biosciences, Inc. in Q1 2021 and held it in 1 quarter.
  • Silverarc Capital Management's Aptose Biosciences, Inc. position peaked at $598K in Q1 2021.
  • 63 funds tracked by Wall St. Rank held Aptose Biosciences, Inc. as of Q2 2021.

Based on Silverarc Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.